Jeff Lazarus: 'The Human and Economic Burden of MASLD/MASH'

Jeffrey V. Lazarus for presents 'The Human and Economic Burden of MASLD/MASH' at the Fatty Liver Alliance and CanNASH Second Annual Primary Care NAFLD and NASH Summit.

Professor Lazarus began with a quick overview of the new nomenclature and explaining that it came to be as a way of "avoiding stigma and making the name more accurate and more precise...".

"We can risk stratify the most serious cases to specialists care and everyone else will stay in Primary Care."

"We need to think about the public health perspective."

Global prevalence rates of MASLD and MASH in patients with T2 Diabetes:
"62.25% have MASLD"
"37.3% have MASH"
"17.0% have advanced fibrosis"

"High risk groups/factors for MASLD/MASH progression include; lifestyle, diabetes melitus, genetic modifiers, male sex, obesity, iron overload, older age, alcohol, and drugs."